Suppr超能文献

顽固性肾病性水肿状态下利尿剂的联合应用:病例报告

Combination of Diuretics in States of Resistant Nephrotic Edema: a Case Presentation.

作者信息

Fratila Valentina-Georgiana, Lupusoru Gabriela, Sorohan Bogdan Marian, Obrisca Bogdan, Mocanu Valentin, Lupusoru Mircea, Ismail Gener

机构信息

Department of Nephrology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Department of Nephrology, Fundeni Clinical Institute, Bucharest, Romania.

出版信息

Maedica (Bucur). 2024 Sep;19(3):641-647. doi: 10.26574/maedica.2024.19.3.641.

Abstract

While there remains no universally accepted definition for resistant edema, it is generally acknowledged as edema that fails to respond to maximally administered doses of diuretics. Nephrotic edema is characterized by high levels of proteinuria, notably urinary concentrations of serine proteases, which possess the ability to activate the epithelial sodium channel (ENaC), resulting in persistent fluid retention. Loop diuretics are typically preferred as first-line therapy for hypervolemia. However, the sustained activation of ENaC channels may lead to resistance to treatment. Consequently, the blockade of ENaC represents a potential therapeutic approach. We report the case of a 36-year-old man presenting with nephrotic edema managed with a combination of furosemide and human albumin. Despite an initially favorable response, the patient subsequently developed oliguria and progressive weight gain. On the third day, a regimen comprising amiloride (5 mg/day) and hydrochlorothiazide (50 mg/day) was initiated, resulting in complete resolution of edema after 11 days. No hyperkalemia was observed, with only a slight elevation in serum creatinine levels. Although clinical trials are limited, mounting evidence from human and animal studies supports the concept of nephrotic syndrome as an overfill phenomenon and underscores the potential benefits of ENaC blockers in the management of nephrotic edema.

摘要

尽管目前对于抵抗性水肿尚无普遍接受的定义,但一般认为它是指对最大剂量利尿剂治疗无反应的水肿。肾病性水肿的特征是蛋白尿水平高,尤其是尿液中丝氨酸蛋白酶的浓度,这些蛋白酶具有激活上皮钠通道(ENaC)的能力,导致持续性液体潴留。袢利尿剂通常是治疗血容量过多的一线首选药物。然而,ENaC通道的持续激活可能导致治疗抵抗。因此,阻断ENaC代表了一种潜在的治疗方法。我们报告了一例36岁男性肾病性水肿患者的病例,该患者接受了速尿和人白蛋白联合治疗。尽管最初反应良好,但患者随后出现少尿和体重逐渐增加。第三天,开始使用氨氯吡咪(5毫克/天)和氢氯噻嗪(50毫克/天)的治疗方案,11天后水肿完全消退。未观察到高钾血症,血清肌酐水平仅略有升高。尽管临床试验有限,但来自人类和动物研究的越来越多的证据支持肾病综合征是一种充盈过度现象的概念,并强调了ENaC阻滞剂在治疗肾病性水肿方面的潜在益处。

相似文献

3
Furosemide and albumin for the treatment of nephrotic edema: a systematic review.速尿和白蛋白治疗肾病性水肿:系统评价。
Pediatr Nephrol. 2022 Aug;37(8):1747-1757. doi: 10.1007/s00467-021-05358-4. Epub 2022 Mar 3.
9
Calcium channel blockers for primary and secondary Raynaud's phenomenon.用于原发性和继发性雷诺现象的钙通道阻滞剂。
Cochrane Database Syst Rev. 2017 Dec 13;12(12):CD000467. doi: 10.1002/14651858.CD000467.pub2.
10
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5.

本文引用的文献

4
Current Perspectives in Management of Edema in Nephrotic Syndrome.当前肾病综合征水肿管理的观点。
Indian J Pediatr. 2020 Aug;87(8):633-640. doi: 10.1007/s12098-020-03252-9. Epub 2020 Mar 30.
7
Diuretic Resistance.利尿剂抵抗
Am J Kidney Dis. 2017 Jan;69(1):136-142. doi: 10.1053/j.ajkd.2016.08.027. Epub 2016 Nov 1.
9
Nonimmunologic targets of immunosuppressive agents in podocytes.足细胞中免疫抑制剂的非免疫靶点
Kidney Res Clin Pract. 2015 Jun;34(2):69-75. doi: 10.1016/j.krcp.2015.03.003. Epub 2015 Apr 9.
10
Amiloride: the "new" renal tonic?氨氯吡咪:“新型”肾滋补剂?
Am J Physiol Renal Physiol. 2015 Sep 1;309(5):F429-30. doi: 10.1152/ajprenal.00237.2015. Epub 2015 Jun 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验